September 24, 2020
BioPharmGuy News
For the last time this month, our newsletter is brought to you by Pfizer CentreOne. Collaborate with Pfizer CentreOne to access steroid and hormone APIs and intermediates with exceptional technical and regulatory support, manufactured in the US under Pfizer quality standards.
BioPharmGuy

Couple things to note.

First, our data prices are going up soon, so if you were considering a purchase, you may want to get a quote now. Quotes are good for a month, so you will have the old prices locked in for that period.

Second, if you have a difficult-to-fill job at your company, we offer a single job posting each month in this newsletter. We see 1500-1600 people reading each email. At $85 per mailing it may be worth a dice roll.

Addition & Attrition
25 companies added, 32 removed after our monthly cull. This week's summary file available on our downloads page.
Industry
Ravata Solutions
Ravata's technology consists of a device that can edit the genes of a mouse embryo. That's a useful technology for research. Just not sure they have their messaging right - their slogan is "Transgenics Today, IVF Tomorrow". Pretty much everyone's worst nightmare about gene-editing is the creation of designer babies, right? So why not remind people of the scariest possible use of your technology. On your homepage. With a human baby as the backdrop.

Oncologie
Never a good idea to name your company a slightly misspelled, existing word. Oncologie rectified their error and renamed themselves OncXerna. Can't go wrong with a random X in a drug company name.

X gon' give it to ya
Speaking of, will X's ever go out of fashion in the biotech/pharma world? We currently list 3699 companies working on some type of drug and amazingly, 12.5% (465) have the letter X in their name. 19 have two. No one yet has the audacity to use three. Someday...

Novellus(es)
A company out of Israel called NovellusDx just got a series C funding for $57M to move their lead product into phase 2. They used to be a diagnostics company, hence the Dx in their name. Now that they moved to therapeutics they seem to be simply going by Novellus.

This Novellus is of course not to be confused with the Novellus based in Cambridge, MA. 

These cases are very annoying here at BioPharmGuy since we do not include inc, co, ltd in company names. Here's hoping they keep the "Dx" for old times' sake.

Nutcracker Therapeutics
How about this company name? They really went all-in putting a nutcracker in their logo and naming their mRNA platform ACORN (Automated Controlled RNA).

Memorable. Great logo. 10/10, would name again.
Health & Science
Covid Dashboards
Was only a matter of time before a website started rating all the Covid dashboards for US colleges and universities. You might say they created a Covid dashboard dashboard. Now we just need a competitor to spring up and BioPharmGuy will be forced to enter the fray and create our own Covid dashboard dashboard dashboard to determine who is the best of the Covid dashboard dashboards.

Azar the Czar
In an attempt to assuage the public's fears of political interference with vaccine approvals, the FDA came out with a guidance on the guidelines they will follow in approving a Covid vaccine. 

The day before, Alex Azar, the Health & Human Services chief, (under which the FDA sits) asserted his authority over the FDA's ability to make rules and declared they will henceforth all require his personal approval.

Certainly whoever at FDA came out with the new vaccine guidance meant well and they were conducting their job as they have done for years. But if you think that guidance will stand up to the unprecedented political pressure being heaped onto the FDA right now, you will likely be disappointed.

It's becoming more evident by the day that if any drug company submits a Covid-19 vaccine to FDA for approval it will receive an emergency use authorization no matter what. That is the antithesis of the whole reason for the FDA's existence and is both sad and scary.

The worst part of this whole FDA politicization is if a vaccine is found to truly be both safe and effective, there is a much, much greater proportion of the population from both sides of the political aisle who will not trust that judgement and not get vaccinated. It's literally the last thing we needed. Yet here we are.

Hypocrisy Overload
Confirmed by multiple news sources that a PR official who has been with the National Institute of Allergy and Infectious Diseases for 13 years was an anti-Fauci online troll. 

Everyone is entitled to their opinions, but referring to his own boss as "attention-grubbing and media-whoring Anthony Fauci" as well as a "mask Nazi" meant things were not gonna end well for this dude. It's one thing to offer your opinions, it's another to attempt to annihilate your own employer's credibility. 

He 'retired' immediately after the news broke. 

FDA diagnostic listing
The FDA is keeping track of detection limits for nasal/nasopharyngeal swab-based Covid tests. They list the sensitivity of all as you scroll down to Table 2 here. The nasal tests are way more sensitive than the saliva-based ones.

Trials in Trouble, Unless...
As a result of the pandemic, clinical trials are in deep trouble according to Phesi. They say cancellations are piling up and costs will spiral out of control if companies fail to become more data-driven. As luck would have it, yes, Phesi does happen to offer the very services that would help clinical research companies mitigate these issues. How serendipitous!
Subscribe
If you were forwarded this email and would like to join our mailing list, here's our sign-up page: https://biopharmguy.com/subscribe.php
Premium Listings Always Available
Promote your Company's Listing
Check your website analytics - we are likely one of your top referrers. You can quickly double or triple those referrals with a Premium Listing. You can try it for as short as one month. Full summary of all our upgrade options available here: Promoted Listings. Reply to this email or send a message if interested.